For how we live.
In a 28-patient single-arm phase 2 study, disitamab vedotin with tislelizumab produced a complete response in 73% of evaluable HER2-positive bladder cancers that could not be resected. There was no comparator.
In the publicly funded SWOG S1600 trial, specialised immunonutrition before and after radical cystectomy left 30-day complication rates essentially unchanged: 62% versus 58% on a standard drink.
Smoking is the leading modifiable cause, and the most common presenting sign is blood in the urine. There is no recommended screening test, which makes that sign the thing to act on.
In KEYNOTE-B15/EV-304, perioperative enfortumab vedotin plus pembrolizumab lifted two-year event-free survival to 79.4% from 66.2% against standard cisplatin-based chemotherapy in patients fit for it.
The European Medicines Agency's March meeting produced five positive opinions, three of them for orphan-designated cancer and rare-disease treatments already available in some other markets.
In KEYNOTE-905/EV-303, adding enfortumab vedotin and pembrolizumab to surgery lifted two-year event-free survival to 74.7% from 39.4%. Serious side effects were common.